GlassScriptPhysician profile
Eduardo C Gonzalez
NPI 1235167214
$686.04
in general payments reported to CMS, 2019-2025
12 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2023: $49.89 · 2024: $183 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $466.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $190.90 | 2019 | |
| Sanofi-Aventis U.S. LLC | $108.66 | 2024-2025 | |
| Amgen INC. | $99.61 | 2024-2025 | Krystexxa, Repatha |
| Novo Nordisk INC | $70.94 | 2023-2025 | Wegovy |
| Dynavax Technologies Corporation | $49.38 | 2024-2025 | Heplisav-B |
| Recor Medical INC | $40.08 | 2024 | Paradise Renal Denervation System |
| Exact Sciences Corporation | $34.35 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.30 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $17.10 | 2024 | |
| Novartis Pharmaceuticals Corporation | $15.07 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.04 | 2025 | Airsupra |
| Lilly USA, LLC | $14.61 | 2024 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.